Galactose-1-phosphate Uridyltransferase (GALT) Gene Mutation Analysis
Classic galactosemia is an autosomal recessive disorder of carbohydrate metabolism caused by a deficiency of enzymes involved in galactose utilization. The disorder is caused by the deficiency of galactose-1-phoshate uridylyltransferase (GALT) enzyme resulting in accumulation of galactose-1-phosphate, galactose, galactitol, and galactonate. The GALT gene is mapped on chromosome 9. More than 230 mutations in the GALT gene have been associated with GALT deficiency.
Table 1 shows classification (according to Berry), most common genotypes, and some characteristics of galactosemia. Q188R and K285N mutations account for more than 70% of G alleles in the white population. Affected infants are at risk for lethal E. coli sepsis, cataracts, damage to the liver, kidneys, brain and ovaries, and long-term complications including cognitive, developmental, and reproductive defects. The only current treatment is the removal of galactose and lactose from the diet. Almost 100% detection of galactosemia is found if this test is included in a newborn screening program.
Classifications: Frequent genotype / Characteristics
Classic (OMIMID: 230400): Q188R K28 / In Europeans, at risk of acute and chronic complications, almost total absence of GALT activity
Clinical: S135L / In Blacks, lack of some chronic complications, normal [14C] galactose breath test
Biochemical: N314D N314D/Q18 / Durate, more frequent than classic variant, mild phenotype
In classic galactosemia, GALT activity is nearly absent. Affected infants present at 3–14 days old with poor feeding, vomiting, diarrhea, jaundice, lethargy progressing to coma, and abdominal distension with hepatomegaly usually followed by progressive liver failure. Risk is also increased for Escherichia coli or other gram-negative neonatal sepsis. Elimination of galactose from the diet reverses growth failure, renal and hepatic dysfunction, and cataracts. However, patients can still have ovarian failure (primary or secondary amenorrhea), mental retardation, speech dyspraxia, ataxia, and learning disabilities. Diet must be continued for life. Patients are periodically monitored by measuring levels of galactose-1-phosphate in red blood cells; intrinsic production may cause abnormally high values even with dietary galactose restriction. When the diagnosis is not made at birth, liver disease and brain damage may become irreversible.
- Diagnosis of galactosemia
- Carrier screening for galactosemia
Mutation detection confirms diagnosis of galactosemia.
Secondary causes of hypergalactosemia should be remembered (congenital hepatitis and hepatic arterio-venous malformations, patent ductus venosus, Tyrosinemia type I, and Fanconi–Bickel syndrome).
Mutation not detected (Negative for mutations analyzed)
Whole blood collected with anticoagulants, lavender top tube (EDTA).
Stability
- Ambient: 5 days
- Refrigerated: 7-14 days
- Hum Mutat. 1999;13(6):417-30. [PMID: 10408771]
- Genet Med. 1998 Nov-Dec;1(1):40-8. [PMID: 11261429]
- IUBMB Life. November 2011; 63(11): 949–954. [PMID: 21960482]
- Mol Genet Metab. 2012 May;106(1):7-11. [PMID: 22483615]
- Atlas of genetic diagnosis and counseling (Humana press). 2006: 437-441